Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of
report (Date of earliest event reported): April 17, 2019
CORMEDIX
INC.
|
(Exact
Name of Registrant as Specified in Charter)
|
|
|
|
Delaware
|
001-34673
|
20-5894890
|
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
|
|
400
Connell Drive, Suite 5000, Berkeley Heights, NJ
|
07922
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant’s
Telephone Number, Including Area Code: (908) 517-9500
|
(Former
Name or Former Address, If Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On
April 17, 2019, we issued a press release to report the
completion of our previously announced
sale of $5.4 million of NOL tax benefits through the New Jersey
Economic Development Authority Program. As a result, we received approximately $5.1
million in cash from the sale of these NOL tax
benefits.
A copy
of the press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
Item 9.01.
Financial Statements and
Exhibits.
Exhibit
No.
|
Description
|
|
|
|
Press
release dated April 17, 2019.
|
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: April 17,
2019
|
CORMEDIX
INC.
|
|
|
|
|
|
/s/ Robert W. Cook
Name:
Robert W. Cook
Title:
Chief Financial Officer
|
|